Use of Antiemetic Agents in Acute Gastroenteritis: A Systematic Review and Meta-analysis | Acid Base, Electrolytes, Fluids | JAMA Pediatrics | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.238.77. Please contact the publisher to request reinstatement.
1.
King  CKGlass  RBresee  JSDuggan  C Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy.  MMWR Recomm Rep 2003;52 ((RR-16)) 1- 16PubMedGoogle Scholar
2.
Malek  MACurns  ATHolman  RC  et al.  Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000.  Pediatrics 2006;117 (6) 1887- 1892PubMedGoogle Scholar
3.
Black  REMorris  SSBryce  J Where and why are 10 million children dying every year?  Lancet 2003;361 (9376) 2226- 2234PubMedGoogle Scholar
4.
Ozuah  POAvner  JRStein  RE Oral rehydration, emergency physicians, and practice parameters: a national survey.  Pediatrics 2002;109 (2) 259- 261PubMedGoogle Scholar
5.
Reis  ECGoepp  JGKatz  SSantosham  M Barriers to use of oral rehydration therapy.  Pediatrics 1994;93 (5) 708- 711PubMedGoogle Scholar
6.
Kwon  KTRudkin  SELangdorf  MI Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians.  Clin Pediatr (Phila) 2002;41 (9) 641- 652PubMedGoogle Scholar
7.
Li  STDiGiuseppe  DLChristakis  DA Antiemetic use for acute gastroenteritis in children.  Arch Pediatr Adolesc Med 2003;157 (5) 475- 479PubMedGoogle Scholar
8.
Alhashimi  DAlhashimi  HFedorowicz  Z Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.  Cochrane Database Syst Rev 2006;18 (4) CD005506PubMedGoogle Scholar
9.
US Food and Drug Administration, FDA patient safety news: warning on using phenergan in children under two. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=324. Accessed August 30, 2007
10.
Roila  FFeyer  PMaranzano  E  et al.  Antiemetics in children receiving chemotherapy.  Support Care Cancer 2005;13 (2) 129- 131PubMedGoogle Scholar
11.
Kovac  AL Management of postoperative nausea and vomiting in children.  Paediatr Drugs 2007;9 (1) 47- 69PubMedGoogle Scholar
12.
US Food and Drug Administration, Prescribing information: Zofran (ondansetron hydrochloride). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_06_06_KP%20Ondansetron%20FDA%20label%208-22-06.pdf. Accessed March 18, 2006
13.
Stork  CMBrown  KMReilly  THSecreti  LBrown  LH Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children.  Acad Emerg Med 2006;13 (10) 1027- 1033PubMedGoogle Scholar
14.
Reeves  JJShannon  MWFleisher  GR Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial.  Pediatrics 2002;109 (4) e62http://www.pediatrics.org/cgi/content/full/109/4/e62. Accessed October 1, 2006PubMedGoogle Scholar
15.
Ramsook  CSahagun-Carreon  IKozinetz  CAMoro-Sutherland  D A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis.  Ann Emerg Med 2002;39 (4) 397- 403PubMedGoogle Scholar
16.
Freedman  SBAdler  MSeshadri  RPowell  EC Oral ondansetron for gastroenteritis in a pediatric emergency department.  N Engl J Med 2006;354 (16) 1698- 1705PubMedGoogle Scholar
17.
Cubeddu  LXTrujillo  LMTalmaciu  I  et al.  Antiemetic activity of ondansetron in acute gastroenteritis.  Aliment Pharmacol Ther 1997;11 (1) 185- 191PubMedGoogle Scholar
18.
Roslund  GHepps  TS McQuillen  KK The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial [published online ahead of print November 12, 2007].  Ann Emerg Med PubMed10.1016/j.annemergmed.2007.09.010Google Scholar
19.
Downs  SHBlack  N The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.  J Epidemiol Community Health 1998;52 (6) 377- 384PubMedGoogle Scholar
20.
Agency for Healthcare Research and Quality, Fact sheet: rating the strength of scientific research findings. http://www.ahrq.gov/clinic/epcsums/strenfact.pdf. Accessed August 30, 2007
21.
Verhagen  APde Vet  HCde Bie  RABoers  Mvan den Brandt  PA The art of quality assessment of RCTs included in systematic reviews.  J Clin Epidemiol 2001;54 (7) 651- 654PubMedGoogle Scholar
22.
Verhagen  APde Vet  HCde Bie  RA  et al.  The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus.  J Clin Epidemiol 1998;51 (12) 1235- 1241PubMedGoogle Scholar
23.
Tibbs  RC A clinical comparison of rectal pyrilamine maleate and trimethobenzamide hydrochloride for the control of vomiting in children.  J Miss State Med Assoc 1969;10 (4) 130- 132PubMedGoogle Scholar
24.
Tibbs  RC Rectal pyrilamine-pentobarbital compared with promethazine for vomiting in children.  South Med J 1968;61 (10) 1068- 1071PubMedGoogle Scholar
25.
Van Eygen  MDhondt  FHeck  EAmeryckx  LVan Ravensteyn  H A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children.  Postgrad Med J 1979;55 ((suppl 1)) 36- 39PubMedGoogle Scholar
26.
Dhondt  FTraen  SVanEygen  MBaran  DWillaert  H Domperidone (R-33812) suppositories: an effective antiemetic agent in diverse pediatric conditions: multicenter trial.  Curr Ther Res Clin Exp 1978;24912- 923Google Scholar
27.
Ginsburg  CMClahsen  J Evaluation of trimethobenzamide hydrochloride (Tigan) suppositories for treatment of nausea and vomiting in children.  J Pediatr 1980;96 (4) 767- 769PubMedGoogle Scholar
28.
 Phenergan (promethazine HCl) [package insert].  Madison, NJ Wyeth Pharmaceuticals2004;
29.
US Food and Drug Administration, FDA announces that companies must stop marketing suppository products containing trimethobenzamide. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01601.html. Accessed September 1, 2007
30.
Szajewska  HGieruszczak-Bialek  DDylag  M Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children.  Aliment Pharmacol Ther 2007;25 (4) 393- 400PubMedGoogle Scholar
31.
Als-Nielsen  BChen  WGluud  CKjaergard  LL Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?  JAMA 2003;290 (7) 921- 928PubMedGoogle Scholar
32.
Ridker  PMTorres  J Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.  JAMA 2006;295 (19) 2270- 2274PubMedGoogle Scholar
33.
 Drug pricing for ondansetron. http://www.drugstore.com. Accessed September 1, 2007
Review
September 1, 2008

Use of Antiemetic Agents in Acute Gastroenteritis: A Systematic Review and Meta-analysis

Author Affiliations

Author Affiliations: Division of General Pediatrics and Adolescent Medicine, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine (Drs DeCamp, Byerley, and Steiner). Ms Doshi is a medical student at the University of North Carolina at Chapel Hill School of Medicine.

Arch Pediatr Adolesc Med. 2008;162(9):858-865. doi:10.1001/archpedi.162.9.858
Abstract

Objective  To perform a systematic review and meta-analysis to determine whether taking antiemetic drugs reduces vomiting and decreases the need for further intervention in children with gastroenteritis without causing significant adverse effects.

Data Sources  Computerized databases, reference lists, and expert recommendations.

Study Selection  Prospective controlled trials evaluating medication use in children with vomiting from gastroenteritis.

Intervention  Antiemetic drug therapy.

Main Outcome Measures  Emesis cessation, use of intravenous fluid for rehydration, hospital admission, return to care, and medication adverse effects.

Results  The 11 articles that met the inclusion criteria evaluated various antiemetic agents: ondansetron (n = 6), domperidone (n = 2), trimethobenzamide (n = 2), pyrilamine-pentobarbital (n = 2), metoclopramide (n = 2), dexamethasone (n = 1), and promethazine (n = 1). Meta-analysis of 6 randomized, double-masked, placebo-controlled trials of ondansetron demonstrated decreased risk of further vomiting (5 studies; relative risk [RR], 0.45; 95% confidence interval [CI], 0.33-0.62; number needed to treat [NNT] = 5), reduced need for intravenous fluid (4 studies; RR, 0.41; 95% CI, 0.28-0.62; NNT = 5), and decreased risk of immediate hospital admission (5 studies; RR, 0.52; 95% CI, 0.27-0.95; NNT = 14). Diarrheal episodes increased in ondansetron-treated patients in 3 studies. Ondansetron use did not significantly affect return to care (5 studies; RR, 1.34; 95% CI, 0.77-2.35).

Conclusions  Ondansetron therapy decreases the risk of persistent vomiting, the use of intravenous fluid, and hospital admissions in children with vomiting due to gastroenteritis. Future treatment guidelines should incorporate ondansetron therapy for select children with gastroenteritis.

×